Latest Medical Imaging News

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.

Resonance Health is expanding its clinical trial operations with a third TrialsWest site in Mandurah, WA, set to open in August 2025, enhancing participant recruitment and supporting ongoing pharmaceutical trials.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Enlitic has completed its $10 million capital raise, triggering a $2 million advance payment from GE HealthCare and cementing a strategic collaboration with significant revenue potential.

HyTerra Limited has reported unexpectedly high helium concentrations of up to 4.4% in its Blythe 13-20 well in Kansas, marking a significant extension of the helium play in Eastern Kansas. The company plans to convert the well into an appraisal site to further evaluate this promising discovery.

Pro Medicus has secured a landmark 10-year, A$170 million contract to deploy its cloud-based Visage 7 imaging platform across UCHealth’s extensive hospital network in the US Rocky Mountain region.

Pro Medicus Limited has renewed a significant five-year contract with Franciscan Missionaries of Our Lady Health System, marking a strategic shift to cloud-based medical imaging solutions and promising new revenue streams.

Optiscan Imaging Ltd has commenced a landmark clinical study at Royal Melbourne Hospital, testing its cutting-edge InVue® and InForm™ devices to improve breast cancer surgery precision. The study aims to generate critical data for US FDA approval and could redefine surgical oncology workflows.

Singular Health Group has completed a $7.85 million capital raising through a new share issue, alongside additional funds from option exercises, strengthening its financial position for growth in medical imaging technology.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.